Literature DB >> 20693440

Endopeptidase activities of botulinum neurotoxin type B complex, holotoxin, and light chain.

Hai-Hong Wang1, Stephen Riding, Paul Lindo, Bal Ram Singh.   

Abstract

Botulinum neurotoxin (BoNT) serotype B (BoNT/B) is one of the serotypes of BoNT that causes deadly human botulism, though it is used clinically for treatment of many neuromuscular diseases. BoNT/B is produced by Clostridium botulinum, and it is secreted along with a group of neurotoxin-associated proteins (NAPs) in the form of a BoNT/B complex. The complex dissociates into a 150-kDa holotoxin and NAPs at alkaline pHs. The 150-kDa BoNT/B holotoxin can be nicked to produce a 50-kDa domain referred to as the light chain (LC) and a 100-kDa heavy chain, with the former possessing a unique endopeptidase activity. The two chains remain linked through a disulfide bond that can be reduced to separate the two chains. The endopeptidase activity is present in all three forms of the toxin (complex, purified BoNT/B holotoxin, and separated light chain), which are used by different researchers to develop detection methods and screen for inhibitors. In this research, the endopeptidase activities of the three forms, for the first time, were compared under the same conditions. The results show that enzyme activities of the three forms differ significantly and are largely dependent on nicking and disulfide reduction conditions. Under the conditions used, LC had the highest level of activity, and the complex had the lowest. The activity was enhanced by nicking of BoNT/B holotoxin and was enhanced even more by dithiothreitol (DTT) reduction after nicking. This information is useful for understanding the properties of BoNT endopeptidases and for comparing the efficacies of different inhibitors when they are tested with different forms of BoNT endopeptidase.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20693440      PMCID: PMC2950459          DOI: 10.1128/AEM.00731-10

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  17 in total

Review 1.  Botulinum toxin type B (Myobloc): pharmacology and biochemistry.

Authors:  James E Callaway
Journal:  Clin Dermatol       Date:  2004 Jan-Feb       Impact factor: 3.541

2.  Crystal structure of Clostridium botulinum neurotoxin protease in a product-bound state: Evidence for noncanonical zinc protease activity.

Authors:  Brent Segelke; Mark Knapp; Saloumeh Kadkhodayan; Rod Balhorn; Bernhard Rupp
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-23       Impact factor: 11.205

3.  Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia.

Authors:  C L Comella; J Jankovic; K M Shannon; J Tsui; M Swenson; S Leurgans; W Fan
Journal:  Neurology       Date:  2005-11-08       Impact factor: 9.910

4.  Analysis of the substrate recognition domain determinants of botulinum type B toxin using phage display.

Authors:  E R Evans; J M Sutton; A Gravett; C C Shone
Journal:  Toxicon       Date:  2005-09-15       Impact factor: 3.033

5.  Intestinal absorption of botulinum toxins of different molecular sizes in rats.

Authors:  S Sugii; I Ohishi; G Sakaguchi
Journal:  Infect Immun       Date:  1977-09       Impact factor: 3.441

6.  Development of novel assays for botulinum type A and B neurotoxins based on their endopeptidase activities.

Authors:  B Hallis; B A James; C C Shone
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

7.  Separation, purification, partial characterization and comparison of the heavy and light chains of botulinum neurotoxin types A, B, and E.

Authors:  V Sathyamoorthy; B R DasGupta
Journal:  J Biol Chem       Date:  1985-09-05       Impact factor: 5.157

8.  Peptide substrate specificity and properties of the zinc-endopeptidase activity of botulinum type B neurotoxin.

Authors:  C C Shone; A K Roberts
Journal:  Eur J Biochem       Date:  1994-10-01

9.  Detection of type A, B, E, and F Clostridium botulinum neurotoxins in foods by using an amplified enzyme-linked immunosorbent assay with digoxigenin-labeled antibodies.

Authors:  Shashi K Sharma; Joseph L Ferreira; Brian S Eblen; Richard C Whiting
Journal:  Appl Environ Microbiol       Date:  2006-02       Impact factor: 4.792

10.  Efficacy of a novel metalloprotease inhibitor on botulinum neurotoxin B activity.

Authors:  M Adler; J D Nicholson; F Cornille; B E Hackley
Journal:  FEBS Lett       Date:  1998-06-16       Impact factor: 4.124

View more
  3 in total

1.  A Novel Surface Plasmon Resonance Biosensor for the Rapid Detection of Botulinum Neurotoxins.

Authors:  Kruti Patel; Shmuel Halevi; Paul Melman; John Schwartz; Shuowei Cai; Bal Ram Singh
Journal:  Biosensors (Basel)       Date:  2017-08-07

2.  Optimization of SNAP-25 and VAMP-2 Cleavage by Botulinum Neurotoxin Serotypes A-F Employing Taguchi Design-of-Experiments.

Authors:  Laura von Berg; Daniel Stern; Jasmin Weisemann; Andreas Rummel; Martin Bernhard Dorner; Brigitte Gertrud Dorner
Journal:  Toxins (Basel)       Date:  2019-10-11       Impact factor: 4.546

3.  Hypersensitive detection and quantitation of BoNT/A by IgY antibody against substrate linear-peptide.

Authors:  Tao Li; Hao Liu; Kun Cai; Maoren Tian; Qin Wang; Jing Shi; Xiang Gao; Hui Wang
Journal:  PLoS One       Date:  2013-03-21       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.